NCT01469793View on ClinicalTrials.gov

A Study of DMOT4039A in Participants With Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer

PHASE1CompletedINTERVENTIONAL

Enrollment

71

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions

Ovarian Cancer

Interventions

DRUG

DMOT4039A

DMOT4093A will be administered by intravenous infusion on either a Q3W or a Q1W dosing schedule, in 21-day cycles.

Trial Locations (6)

32224

Jacksonville

55905

Rochester

80045

Aurora

85259

Phoenix

1081 HV

Amsterdam

9713 GZ

Groningen

Sponsors

Lead Sponsor

Genentech, Inc.

All Listed Sponsors

lead

Genentech, Inc.

INDUSTRY